WELCOME
ON THE CONDOR PROGRAM WEBSITE
CONDOR project wants to revolutionize by 2027 the therapeutic management of soft tissue sarcomas (STS) patients.
STS are rare tumours of mesenchymal origin, comprising ~1% of all adult cancers and 15% in children, +4,500 adults and children each year in France, and 500,000 worldwide. Up to 40% of STS patients will develop metastatic disease.
0
PARTNERS
0
WORK PACKAGES
>0
BIOLOGICAL SAMPLES
THE PROJECT
1 coordinator + 7 strategic partners = 1 objective:
Establishing immunotherapy as a standard for sarcoma
This project has benefited from a government grant managed by the French National Research Agency (ANR)
under the 3rd Investments for the Future program (PIA) , integrated into France 2030
with the reference ANR-21-RHUS-0010.
